Credit: Biophotonics Imaging Laboratory, Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign.
This work marks a major step toward providing cancer researchers with a new tool for tracking tumor progression and physicians new technology for tissue pathology and diagnostics. Typically, the process for diagnosing cancer takes several days. A surgeon first removes a tissue sample that is then processed with chemical dyes; later, the sample is sent to a pathologist for examination and subsequent diagnosis.
"We believe that capturing the dynamic cellular and molecular features in freshly removed or biopsied tissue specimens contains valuable diagnostic and prognostic information that is currently lost when specimens are placed in a fixative and essentially killed quickly in order to preserve structure," said Boppart, who is also a faculty member at the Beckman Institute for Advanced Science and Technology at Illinois and a professor of electrical & computer engineering (ECE) and the Carle Illinois College of Medicine. "Our imaging platform and methodology allow us to extract this new information in real-time, at the point-of-procedure."
Boppart's portable optical imaging system uses precise light pulses to simultaneously image tissue in four modalities, enabling his team to study concurrent processes within cells and tissue that make up the tumor microenvironment. For example, collagen fibers appear in green; elastin fibers and flavin adenine dinucleotide-containing cell cytoplasm appear in yellow; cell membranes, lipid boundaries, and extracellular vesicles (EVs) appear in magenta; and nicotinamide adenine dinucleotide in the cells and lipids appears in cyan.
The team demonstrated the viability of their imaging system in the operating room at Carle Foundation Hospital during breast cancer surgeries. Within 30 minutes of the diseased tissue being extracted, the researchers were able to identify specific tissue features, including molecular signatures associated with metabolic activity inside individual cells that make up the tumor microenivronment.
The researchers were also interested in measuring tumor-related extracellular vesicles (EVs), which are known to promote the spread of cancer. "EVs do play an essential role in cancer progression," said ECE graduate student Yi "Edwin" Sun, the lead author of the research paper. "Quantifying EV densities may be developed as a potential biomarker for future cancer diagnoses." As part of their studies, they also collected and imaged healthy breast tissue that surgeons had removed from cancer-free patients during breast reduction procedures.
In a comparison of the two types of tissue, they found a clear difference in EV density between the cancerous and healthy tissue. For example, the cancerous tissue exhibited increased EV densities and had shorter tumor-to-margin distance. "What we observed about the extracellular vesicles is significant but it could only be accurately determined with our new system," said Sun, noting how other portable optical imaging systems deployed in the operating room all alter the tissue samples either with fluorescent dyes or toxic ultraviolet light. "Our imaging technique works well with current cancer treatment routines and is free of any form of perturbation."
According to Boppart, the team's future plans include using the imaging system on tissue specimens obtained from needle-biopsy procedures that are routinely performed in outpatient settings. They will also continue using the system on samples from the operating room.
Source: University of Illinois at Urbana-Champaign